Literature DB >> 10398587

Structural basis and mechanism of enoyl reductase inhibition by triclosan.

M J Stewart1, S Parikh, G Xiao, P J Tonge, C Kisker.   

Abstract

The enoyl-acyl carrier protein reductase (ENR) is involved in bacterial fatty acid biosynthesis and is the target of the antibacterial diazaborine compounds and the front-line antituberculosis drug isoniazid. Recent studies suggest that ENR is also the target for the broad-spectrum biocide triclosan. The 1.75 A crystal structure of EnvM, the ENR from Escherichia coli, in complex with triclosan and NADH reveals that triclosan binds specifically to EnvM. These data provide a molecular mechanism for the antibacterial activity of triclosan and substantiate the hypothesis that its activity results from inhibition of a specific cellular target rather than non-specific disruption of the bacterial cell membrane. This has important implications for the emergence of drug-resistant bacteria, since triclosan is an additive in many personal care products such as toothpastes, mouthwashes and soaps. Based on this structure, rational design of triclosan derivatives is possible which might be effective against recently identified triclosan-resistant bacterial strains. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10398587     DOI: 10.1006/jmbi.1999.2907

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  66 in total

1.  Location and orientation of Triclosan in phospholipid model membranes.

Authors:  Jaime Guillén; Angela Bernabeu; Stuart Shapiro; José Villalaín
Journal:  Eur Biophys J       Date:  2004-01-09       Impact factor: 1.733

Review 2.  Potential impact of increased use of biocides in consumer products on prevalence of antibiotic resistance.

Authors:  Peter Gilbert; Andrew J McBain
Journal:  Clin Microbiol Rev       Date:  2003-04       Impact factor: 26.132

3.  Structural and enzymatic analyses reveal the binding mode of a novel series of Francisella tularensis enoyl reductase (FabI) inhibitors.

Authors:  Shahila Mehboob; Kirk E Hevener; Kent Truong; Teuta Boci; Bernard D Santarsiero; Michael E Johnson
Journal:  J Med Chem       Date:  2012-06-08       Impact factor: 7.446

4.  Triclosan Computational Conformational Chemistry Analysis for Antimicrobial Properties in Polymers.

Authors:  Richard C Petersen
Journal:  J Nat Sci       Date:  2015-03

Review 5.  Targeting InhA, the FASII enoyl-ACP reductase: SAR studies on novel inhibitor scaffolds.

Authors:  Pan Pan; Peter J Tonge
Journal:  Curr Top Med Chem       Date:  2012       Impact factor: 3.295

Review 6.  The reductase steps of the type II fatty acid synthase as antimicrobial targets.

Authors:  Yong-Mei Zhang; Ying-Jie Lu; Charles O Rock
Journal:  Lipids       Date:  2004-11       Impact factor: 1.880

7.  Oral malodor reduction by a combination of chemotherapeutical and mechanical treatments.

Authors:  Svetlana Farrell; Robert A Baker; Marta Somogyi-Mann; Jon J Witt; Robert W Gerlach
Journal:  Clin Oral Investig       Date:  2006-04-19       Impact factor: 3.573

8.  Crystallization and preliminary X-ray crystallographic analysis of enoyl-ACP reductase III (FabL) from Bacillus subtilis.

Authors:  Kook-Han Kim; Joon Kyu Park; Byung Hak Ha; Jin Ho Moon; Eunice EunKyeong Kim
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2007-02-28

9.  Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors.

Authors:  Christopher W am Ende; Susan E Knudson; Nina Liu; James Childs; Todd J Sullivan; Melissa Boyne; Hua Xu; Yelizaveta Gegina; Dennis L Knudson; Francis Johnson; Charles A Peloquin; Richard A Slayden; Peter J Tonge
Journal:  Bioorg Med Chem Lett       Date:  2008-04-18       Impact factor: 2.823

10.  Crystal structures of Mycobacterium tuberculosis KasA show mode of action within cell wall biosynthesis and its inhibition by thiolactomycin.

Authors:  Sylvia R Luckner; Carl A Machutta; Peter J Tonge; Caroline Kisker
Journal:  Structure       Date:  2009-07-15       Impact factor: 5.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.